IQVIA Named a Leader in Pharmacovigilance Solutions in IDC MarketScape Report
12 September 2023 - 2:30PM
Business Wire
IQVIA™ (NYSE:IQV), a global provider of data, analytics,
technology solutions and services to the life sciences industry,
has been named a Leader in the IDC Marketscape Worldwide Life
Science R&D Pharmacovigilance Solutions 2022 Vendor
Assessment.
Fueled by IQVIA Connected Intelligence™, IQVIA offers a full
suite of PV technologies and services to support end-to-end safety
processes, including the SaaS-based Vigilance Platform which can
harness the power of operational data and targeted insights to help
customers garner deeper understandings, enhance decision making and
discover new opportunities.
Ensuring patient safety is a top priority, yet with the steep
rise in the number of reported adverse events, it is becoming
increasingly difficult to do a timely manual review of each report.
Regulatory requirements around the use of PV data are also
tightening, along with regional regulatory standards around the
world. Automated, intelligent safety solutions rooted in AI/ML
technology are solving the data volume and regulatory compliance
challenges and ensuring PV teams can focus on increasing the safety
of patient treatments rather than exhausting resources to execute
data management.
“IQVIA sees that the industry requires integration across
Safety, Regulatory and Quality, and it will help customers achieve
this through Connected Intelligence. Using operational data,
targeted insights and technology, IQVIA Connected Intelligence aims
to help customers garner deeper insights, enhance decision making,
and discover new opportunities,” said Dr. Nimita Limaye, Research
VP, Life Sciences R&D Strategy and Technology, at IDC.
The IDC Marketscape recommends considering IQVIA when “seeking
deep PV domain expertise and a PV platform that offers end-to-end
capabilities.”
“Used by more than 3,000 safety professionals across over 100
countries, the IQVIA Vigilance Platform simplifies the PV process,
allowing companies to focus on their end goal: delivering safer,
more effective medicines that can improve patient lives,” said Joe
Rymsza, Vice President, Global Safety, Regulatory and Quality
Technology Solutions at IQVIA. “We believe the IDC MarketScape’s
recognition of IQVIA as a Leader underscores our commitment to
solving the industry’s pressing needs through the development of
innovative technology.”
To learn more about IQVIA’s suite of comprehensive PV solutions,
visit our site.
About IDC MarketScape:
IDC MarketScape vendor assessment model is designed to provide
an overview of the competitive fitness of ICT (information and
communications technology) suppliers in a given market. The
research methodology utilizes a rigorous scoring methodology based
on both qualitative and quantitative criteria that results in a
single graphical illustration of each vendor’s position within a
given market. IDC MarketScape provides a clear framework in which
the product and service offerings, capabilities and strategies, and
current Page 6 © IDC Visit us at IDC.com and follow us on Twitter:
@IDC and future market success factors of IT and telecommunications
vendors can be meaningfully compared. The framework also provides
technology buyers with a 360-degree assessment of the strengths and
weaknesses of current and prospective vendors.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 87,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviors and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230912165746/en/
Nick Childs, IQVIA Investor Relations (nick.childs@iqvia.com)
+1.973.316.3828 Trent Brown, IQVIA Media Relations
(trent.brown@iqvia.com) +1.919.780.3221
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
Von Mai 2023 bis Mai 2024